NCT00468611

Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 510 (actual)
• Sponsor: BioMS Technology Corp. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the efficacy and safety of MBP8298 compared to placebo in subjects with Secondary Progressive Multiple Sclerosis (SPMS)

Conditions

• Multiple Sclerosis, Secondary Progressive

Interventions

Type	Name	Description
DRUG	MBP8298	500mg MBP8298 IV every six months for a period of two years

Timeline

• Start date: 2007-06-01
• Primary completion: 2009-07-01
• Completion: 2009-09-01
• First posted: 2007-05-03
• Last updated: 2009-08-13